Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bladder Cancer: early-phase trial registry
74 of 179 indexed Bladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #61 of 28,707 conditions by registered trial count.
179 US clinical trials · 74 currently recruiting · #61 of 28,707 conditions by registered trial count
Bladder Cancer: 179 US clinical trials tracked, 74 recruiting.
Bladder Cancer is the subject of 179 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition bladder-cancer
OPEN 74 | RECR 41% | LATE 14 | EARLY 84 | RANK #61 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Pediatric Obesity (41% recruiting · 46 trials)
Bladder Cancer lists 74 open slots (41% of 179 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bladder Cancer is recruiting above its size-band peers.
74 of 179 indexed trials (41.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Bladder Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 179 trials (9.5%). 92 distinct sponsors appear on at least one study for this condition label.
-
Typical Bladder Cancer enrolment sits around 98 participants.
Median target enrolment is 98 among the 176 trials that report a genuine target (sentinel values excluded). 90 of those (51.1%) plan for fewer than 100 participants.
-
Bladder Cancer research is mostly interventional.
131 interventional and 48 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
179 total, page 4 of 4
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT01589094
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
Celldex Therapeutics
NCT00709462
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
NCT00053209
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
Dana-Farber Cancer Institute
NCT00808639
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
NCT00389155
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
NCT00014144
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03914794
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT00002919
Quality of Life and Symptom Management in Patients With Bladder Cancer
David Latini
NCT00772018
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
NCT00318643
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
NCT00380029
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Memorial Sloan Kettering Cancer Center
NCT00612326
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
Baylor College of Medicine
NCT02885974
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
Dartmouth-Hitchcock Medical Center
NCT02648178
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Poniard Pharmaceuticals
NCT00465725
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
University of Oklahoma
NCT03892642
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT01373294
The Impact of Preoperative Urostomy Education on Patients and Families
University of Kansas Medical Center
NCT04334226
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Near Infrared Fluorescence Imaging for Bladder Cancer Detection
Edward Messing
NCT03058705
A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients
University of Utah
NCT06002269
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT02788201
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma
NCT05136898
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT03023319
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen
NCT03245736
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
NCT00004223
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
Anthra Pharmaceuticals
NCT00003759
R115777 in Treating Patients With Advanced Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT00006376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 45 |
| Phase 3 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Bladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bladder Cancer page
179 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Bladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Bladder Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bladder Cancer condition card totals 179 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.